The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- Guardant Liquid Biopsy Test Approved as CDx for Targeted Colorectal Cancer Drugs
October 17, 2023
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Meiji/KM’s XBB.1.5-Tailored COVID Jab to Enter Pediatric PIII Study
October 17, 2023
- EU Panel Backs Astellas’ Hot Flash Drug
October 17, 2023
- Oral Flu Drug Prescriptions 17 Times Higher than Pre-COVID: September Survey
October 16, 2023
- Japan Pharma Market to Contract after 2027 on Biosimilar Influx: Fuji Keizai
October 13, 2023
- Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
- Viatris to Discontinue 28 APIs/48 Products for Supply, Productivity Reasons
October 12, 2023
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
- Astellas, Shared Lab Operators Link Up on Life Science Ecosystem
October 12, 2023
- Donanemab’s Limited Duration of Dosing Benefits Patients on Safety Front: Lilly CSO
October 11, 2023
- Japan Ethical Drug Sales Surge 8.1% in August: Crecon
October 10, 2023
- Kyowa Kirin to Acquire Orchard to Forge Ahead in Gene Therapy
October 6, 2023
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
- Opdivo Snatches Back Top Spot in Japan Sales Ranking in September: Encise
October 6, 2023
- Sawai Bags CML Nod for Sprycel Generic
October 5, 2023
- JCR to Explore Best Opportunities for Overseas Alliance on JR-171: Exec
October 5, 2023
- Manlio Florenzano Takes Helm of Sandoz Japan as Spin-Off Completes
October 5, 2023
- Nippon Kayaku Buys Stake in Adlai to Drive Cancer Drug Collab
October 5, 2023
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…